Understanding Immune Cell Adaptation to Tumor Hypoxia for Maximized Therapeutic Efficacy of Immunotherapy: Biology and Non-invasive Imaging Application
Cancer Research and Treatment · 15.01.2026 · 58 (1) · 26-47
DOI: 10.4143/crt.2025.200 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Research and Treatment, erschienen am 15.01.2026. Verfasst von Taerim Oh und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, Seoul National University, Seoul, Korea. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Tumor Hypoxia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Seoul National University, Ministry of Science and ICT, Ministry of Education.
Abstract (Originalsprache)
It is extensively documented that tumor hypoxia contributes to the failure of chemotherapy and radiotherapy. Recent evidence suggests that hypoxia is also closely involved in the resistance to immunotherapy. In this review, we highlight how immune cells that are essential for the maximized immunotherapy efficacy, including cytotoxic T cells, dendritic cells, and natural killer cells, can adapt to tumor hypoxia. We then outline previous attempts targeting tumor hypoxia (for example, modulators of tumor cell oxygen consumption, perfusion modulators, hypoxia-activated prodrugs, hypoxia-inducible factor inhibitors, and hypoxia-responsive chimeric antigen receptor T cells) discussing how these approaches have resulted in an improvement of the antitumor response to immunotherapy in preclinical or clinical settings. Lastly, we review various non-invasive techniques to detect the tumor hypoxia and immune responses. We believe that an integration of the biological knowledge of immune cell adaptation to tumor hypoxia with the cutting edge non-invasive imaging technologies may ultimately allow us not only to select for patients who would benefit the most from the immunotherapy but also to monitor their responses in a real-time manner so that we can offer them an optimal personalized medicine in the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Veterinary Medicine, Seoul National University, Seoul, Korea.
- Graduate School of Convergence Science and Technology, Seoul National University, Suwon, Korea.
- Department of Radiation Oncology, Samsung Medical Center, Seoul, Korea.
- Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand.
- Division of Bioengineering and Bioinformatics, Faculty of Information Science and Technology, Hokkaido University, Sapporo, Japan.
- Cancer Research Institute, College of Medicine, Seoul National University, Seoul, Korea.
Förderung
- Seoul National University
- Ministry of Science and ICT
- Ministry of Education
- Japan Society for the Promotion of Science
Zitieren
APA
Oh, T., Kim, M., Kang, G. S., Ye, S. J., Choi, C., Park, W., Hay, M., Hirata, H., & Ahn, G. O. (2026). Understanding Immune Cell Adaptation to Tumor Hypoxia for Maximized Therapeutic Efficacy of Immunotherapy: Biology and Non-invasive Imaging Application. Cancer Research and Treatment, 58(1), 26-47. https://doi.org/10.4143/crt.2025.200
Vancouver
Oh T, Kim M, Kang GS, Ye SJ, Choi C, Park W, et al. Understanding Immune Cell Adaptation to Tumor Hypoxia for Maximized Therapeutic Efficacy of Immunotherapy: Biology and Non-invasive Imaging Application. Cancer Research and Treatment. 2026;58(1):26-47. doi:10.4143/crt.2025.200
BibTeX
@article{Oh2026,
author = {Oh, Taerim and Kim, Minwoo and Kang, Gi-Sue and Ye, Sung-Joon and Choi, Changhoon and Park, Won and Hay, Michael and Hirata, Hiroshi and Ahn, G-One},
title = {Understanding Immune Cell Adaptation to Tumor Hypoxia for Maximized Therapeutic Efficacy of Immunotherapy: Biology and Non-invasive Imaging Application},
journal = {Cancer Research and Treatment},
year = {2026},
volume = {58},
number = {1},
pages = {26--47},
doi = {10.4143/crt.2025.200}
}
EUVIMED